Resumen
Antecedentes: Es clara la eficacia y seguridad del omalizumab en niños mayores de seis años en ensayos clínicos controlados, pero existen pocos estudios de la vida real.
Objetivo: Evaluar la respuesta con la adición del omalizumab en niños con asma moderada a grave persistente, en condiciones de la vida real.
Métodos: Estudio observacional con seguimiento de 12 meses en la vida real en un grupo de 61 niños mayores de seis años en quienes se evaluó el control del asma antes del inicio del tratamiento, a los cuatro y 12 meses.
Resultados: Después de 12 meses de tratamiento con omalizumab hubo mejoría en los síntomas tanto en los menores de 12 años como en los mayores de esta edad (p = 0.001). Disminuyó el consumo de medicamentos controladores en 73 %, en 61 % la dosis de esteroide inhalado y 8 % lo suspendió. Se disminuyó la dosis promedio de esteroide inhalado a 396 ± 298 μg, cambio que fue estadísticamente significativo (p = 0.02).
Conclusión: Omalizumab es un medicamento eficaz, seguro y bien tolerado como terapia adicional para el control clínico del asma alérgica moderada y grave que no ha tenido mejoría con los tratamientos convencionales.
Referencias
Global Strategy for Asthma Management and Prevention 2017. EE. UU.: Global Initiative for Asthma; 2017.
Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17. DOI: 10.1186/1471-2466-12-17
Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy. 2008;63:1054-1060. DOI: 10.1111/j.1398-9995.2008.01672.x
Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36. Disponible en: http://pediatrics.aappublications.org/content/108/2/e36.long
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470-477. DOI: 10.1183/09031936.03.00261903
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015. DOI: 10.1056/NEJMoa1009705
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216. DOI: 10.1016/j.jaci.2009.09.021
Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604-609. DOI: 10.1136/archdischild-2011-301570
Bhutani M, Yang WH, Hébert J, De-Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. PLoS One. 2017;12(8):e0183869. DOI: 10.1371/journal.pone.0183869
Molimard M, De-Blay F, Didier A, Le-Gros V. Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France. Respir Med. 2008;102(1):7-16. DOI: 10.1016/j.rmed.2007.08.006
Brusselle G, Michils A, Louis R, Dupont L, Van-De-Maele B, Delobbe A, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009;103(11):1633-1642. DOI: 10.1016/j.rmed.2009.06.014
Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009;103(11):1725-1731. DOI: 10.1016/j.rmed.2009.05.002
Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410-1416. DOI: 10.1016/j.rmed.2010.04.013
Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49(1):78-82. DOI: 10.3109/02770903.2011.637598
Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, et al. Omalizumab in patients with severe asthma: The XCLUSIVE study. Clin Respir J. 2012;6(4):215-227. DOI: 10.1111/j.1752-699X.2011.00263.x
Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593-610. DOI: 10.1111/all.12815
Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224-1233. DOI: 10.1183/09031936.00149812
Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM. Effect of Omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49(3):288-293. DOI: 10.3109/02770903.2012.660297
López Tiro JJ, Contreras EA, Del-Pozo ME, Gómez-Vera JG, Larenas-Linnemann DL. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr). 2015;43(2):120-126. DOI: 10.1016/j.aller.2013.11.008
European Medicines Agency AEMPS. Anexo I. Ficha técnica o resumen de las características del producto. 2015;1-69. [Consultado 2017 May 28]. Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. En: Walker S (editor). Cochrane Database of Systematic Reviews. Reino Unido: John Wiley & Sons; 2014.
Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362-1370. DOI: 10.1016/j.jaip.2017.02.002
Fried AJ, Oettgen HC. Anti-IgE in the treatment of allergic disorders in pediatrics. Curr Opin Pediatr. 2010;22(6):758-764. DOI: 10.1097/MOP.0b013e3283404201
Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther. 2014;8:197-207. DOI: 10.2147/DDDT.S49409
Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, et al. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy. 2016;46(11):1407-1415. DOI: 10.1111/cea.12774
Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther. 2014;28(2):149-153. DOI: 10.1016/j.pupt.2014.03.003
Hanania NA, Wenzel S, Roseń K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. DOI: 10.1164/rccm.201208-1414OC
Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O’Connor GT, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163-171. DOI: 10.1016/j.jaip.2013.01.011
Bender B, Milgrom H, Rand C. Nonadherence in Asthmatic Patients: Is there a Solution to the Problem ? Ann Allergy, Asthma Immunol [Internet]. 1997 Sep [cited 2017 Jun 17];79(3):177–87. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1081120610630013
Janson SL, Solari PG, Trzaskoma B, Chen H, Haselkorn T, Zazzali JL. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. 2015;114(6):516-521. DOI: 10.1016/j.anai.2015.04.010
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2018 Revista Alergia México